KYOWA KIRIN, INC

Lobbying for KYOWA KIRIN, INC · Pharmaceutical company

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Expenses

$90,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Pharmacy

FDA modernization policy issues. General issues related to rare disease and clinical trials. General issues related to diagnostics for patients with rare diseases. Issues related to drug pricing. Issues related to reform of pharmacy benefit managers. Issues related to trade. Issues related to Newborn Screening and Genetic Testing.

Trade (domestic/foreign)

Issues related to trade.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.